New Wave Biotech
New Wave Biotech builds Bioprocess Foresight, an AI-powered simulation platform that helps biomanufacturers optimize downstream processing, predict yields, and run integrated techno-economic and life cycle assessments. It serves biotech developers, food ingredients, and industrial biotech firms.
- Company typePrivate
- Founded2022
- HeadquartersLondon, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What New Wave Biotech does
New Wave Biotech is a UK-based AI software company founded in 2022 that provides simulation and optimization tools for downstream bioprocessing in biomanufacturing. Its core product, Bioprocess Foresight, is a hybrid AI platform that combines mechanistic scientific models with machine learning to simulate bioprocess scenarios, predict yield, unit economics, and environmental impact, and recommend optimal parameters across 18 downstream unit operations including centrifugation, filtration, chromatography, extraction, and drying. The platform achieves 6.5% prediction error from a single calibration run and 1.4–4X greater accuracy than industry average, validated at 350–700L pilot scale with CPI.
The platform is organized into four integrated modules: AI-Powered Process Simulation, Downstream Process Optimisation, Dynamic Techno-Economic Analysis (TEA), and an industry-first biotech-specific Life Cycle Assessment (LCA) tool aligned with ISO 14040/44 covering 15+ impact categories. New Wave Biotech generates revenue through enterprise SaaS subscriptions, custom optimization projects (multi-year engagements combining virtual and physical experimentation), and direct enterprise licensing. Pricing is quote-based and positioned at a fraction of traditional consultancy costs (TEA reports typically $20k–$40k, consultancy LCA studies $5k–$100k).
The company serves biotech developers (alternative proteins, cultivated meat, precision fermentation), food ingredients and biochemical companies, pharmaceutical and industrial biotechnology firms, and processing technology equipment companies. Named customers include Multus Biotechnology (growth media / cultivated meat, headline case study achieving 8.6X yield improvement, 55% cost reduction, 37.4% processing time reduction) and Liven Proteins (plant-based collagen). Strategic partnerships with CPI, Nurasa (Temasek-owned, Asia-Pacific), iMEAN (upstream strain design), EIT Food, Innovate UK, and Big Idea Ventures provide validation, geographic reach, and ecosystem access. The team of 1–10 operates fully remotely across the UK, Sweden, and Brazil, with registered headquarters in Manchester and operational base in London.
New Wave Biotech firmographics
Firmographics- Name
- New Wave Biotech
- Legal name
- New Wave Biotech Ltd
- Website
- https://newwavebiotech.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- New Wave Biotech builds Bioprocess Foresight, an AI-powered simulation platform that helps biomanufacturers optimize downstream processing, predict yields, and run integrated techno-economic and life cycle assessments. It serves biotech developers, food ingredients, and industrial biotech firms.
- Ownership category
- akta.pro rank
New Wave Biotech industry classification
Industry- Product category
- Bioprocess Simulation Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling) (HLAAAJAF)
- akta.pro secondary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where New Wave Biotech is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
New Wave Biotech business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations
Revenue model
- Software Platform Subscription: SaaS-based access to Bioprocess Foresight platform including AI-powered simulation, downstream optimization, TEA, and LCA tools. Subscription model with pricing based on usage scope and feature access.
- Custom Optimization Projects: Tailored work packages designing optimization programs for specific client needs including target production scale, quality requirements, and known process challenges. Includes iterative cycles of virtual experimentation and targeted physical testing with ongoing collaboration.
- Enterprise Licensing: Direct licensing of platform capabilities to enterprise customers for internal use. Enables corporates to leverage historical experimental data to power future R&D and processing technology companies to accelerate sales and R&D.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise SaaS Platform Access |
| Other | Multi-year contract | Custom Optimization Engagement |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels7 records
New Wave Biotech product offering
Product offeringCore offering
New Wave Biotech develops and sells Bioprocess Foresight, an AI-powered bioprocess simulation platform that virtually tests thousands of downstream processing scenarios to predict yield, unit economics and sustainability impact. The platform combines hybrid AI (mechanistic modeling plus machine learning) with integrated techno-economic analysis and biotech-specific life cycle assessment, enabling biomanufacturers to cut R&D experiments by up to 92% and reach optimal processes faster.
Product overview
New Wave Biotech offers a single AI-powered platform called Bioprocess Foresight, structured as a core simulation platform with multiple integrated modules. The platform combines hybrid AI modelling (mechanistic science plus machine learning) with integrated techno-economic analysis and life cycle assessment. The product portfolio consists of four primary modules: (1) AI-Powered Process Simulation — the core simulation engine for virtual scenario testing; (2) Downstream Process Optimisation — automated optimisation across 18 unit operations; (3) Techno-economic Analysis (TEA) — dynamic cost and economic modelling; and (4) Life Cycle Assessment (LCA) — biotech-specific environmental impact analysis. All four modules operate within the unified Bioprocess Foresight platform, sharing data and models so that each optimisation cycle automatically reflects process performance, economics, and sustainability simultaneously.
Differentiator
Problem solved
Functional benefit
Brands
- Bioprocess Foresight: AI-powered downstream process optimisation platform with integrated techno-economic analysis and life cycle assessment for biomanufacturers.
Products and services
- Bioprocess Foresight Platform AI-powered bioprocess simulation platform that simulates thousands of downstream processing scenarios, predicting yield, unit economics, and sustainability impact of the full process. Combines hybrid AI (mechanistic models + machine learning) with integrated techno-economic analysis and life cycle assessment to enable biomanufacturers to run more targeted experiments and reach optimal processes faster with 92% fewer experiments. Sold to R&D teams, sustainability directors, and operations leaders at biotech, food ingredients, alternative protein and pharmaceutical companies.
- Custom Optimization Projects Project-based professional service engagements where New Wave Biotech designs tailored optimization programs for specific client needs, including target production scale, quality requirements and known process challenges. Engagements combine iterative cycles of in-silico virtual experimentation with targeted physical testing in close collaboration with the client's R&D team.
Quantifiable outcome
- 55% unit cost reduction
- +6 more outcomes
Companies that use New Wave Biotech
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
New Wave Biotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature5 records
New Wave Biotech partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- iMEANcoreStrategic partnership connecting iMEAN's upstream metabolic modeling and strain design capabilities with New Wave Biotech's downstream process optimization, TEA, and LCA. Joint proposition gives teams visibility from organism design through to purification, cost, and sustainability from day one. Addresses the gap where organism design decisions cascade into purification complexity. Available for food ingredients, industrial biotechnology, cosmetics, and pharmaceuticals.
- CPI (Centre for Process Innovation)corePartnership to address lipid extraction challenges in industrial biotechnology. Combines CPI's downstream processing expertise with New Wave Biotech's hybrid AI-powered simulation platform to optimize solvent and non-solvent extraction methods. Project aims to enhance scalability, cost efficiency, and sustainability. Supported by Innovate UK grant under UKRI National Engineering Biology Programme. Validation achieved 6.5% prediction error and 1.4-4X accuracy vs industry average.
- NurasacoreCommercial partnership with Temasek-owned sustainable food and nutrition company. Nurasa gains access to Bioprocess Foresight platform for their ecosystem of food-tech innovators. New Wave Biotech gains access to Nurasa's Asia-wide network, food-grade pilot facilities, application expertise, and regulatory/GTM partnerships. Helps move promising food-tech ingredients from R&D to market-ready products. Joint whitepaper on 'Lean Startup Meets Food Tech' published.
- Multus BiotechnologycoreInnovate UK-backed partnership to scale cultivated meat production using AI bioprocess optimization. New Wave Biotech optimizes downstream processes for Multus's growth media products. Achieved 8.6X yield improvement, 55% cost reduction, 37.4% processing time reduction. Project funded through Innovate UK Engineering Biology grant. Both companies supported by Big Idea Ventures.
Scale indicators11 records
Recent moves6 records
Expansion highlights6 records
New Wave Biotech competitors and assessment
Company assessmentDirect peers
- Culture Biosciences: Cloud bioreactor platform that runs fermentation experiments remotely for biotech customers, accelerating bioprocess development and scale-up. Directly comparable to New Wave Biotech's mission of replacing slow, expensive wet-lab experimentation with faster, more data-rich bioprocess decision-making.
- Synthace: Cloud-based lab automation platform that designs and runs biology experiments using DOE methodologies, enabling scientists to automate R&D workflows. Overlaps directly with New Wave's AI-powered bioprocess simulation and experiment optimization, serving the same biology R&D buyer.
- Benchling: Cloud R&D platform for biotech with ELN, LIMS, and workflow capabilities sold to biopharma R&D teams. Comparable in that both are SaaS infrastructure for biotech R&D decision-making, though Benchling focuses on data management rather than bioprocess simulation specifically.
Emerging players
- Cradle: AI/ML platform for protein engineering and biology design. Comparable as a generative AI company serving biotech R&D teams using ML to compress experimental timelines, though Cradle is focused upstream on protein design rather than downstream process optimization.
- Insitro: ML-driven drug discovery and development platform combining high-throughput biology with machine learning. Comparable as an AI/ML company applying data-driven methods to compress biology R&D cycles, though focused upstream on target/drug discovery rather than bioprocess.
Broad incumbents
- Aspen Technology: Established process simulation software vendor serving chemicals, petrochemicals, and increasingly biopharma. Comparable as the incumbent process-simulation layer New Wave Biotech is targeting specifically for bioprocesses, with overlapping techno-economic capabilities.
- Ginkgo Bioworks: Large synthetic biology platform with internal bioprocess optimization capabilities and a code base (Ginkgo Enzyme Catalysis platform) that competes for similar synthetic biology customers. Comparable as a broader end-to-end synbio platform but with internal rather than externalized software tooling.
- Sartorius: Major bioprocessing equipment and solutions provider increasingly bundling digital and data analytics capabilities (e.g., BIOSTAT, PAT software) with its bioreactors. Comparable as a bioprocess technology incumbent with the resources to expand into process simulation and optimization.
- Cytiva: Global bioprocessing solutions provider (part of Danaher) with digital tools for process development and manufacturing. Comparable as a major bioprocess equipment and services player whose installed base and digital offerings overlap with New Wave's target customers.
Others
- TetraScience: Cloud-native data platform for life sciences R&D and manufacturing that aggregates scientific data into a unified lakehouse. Comparable as enabling biopharma R&D data infrastructure, though TetraScience focuses on the data layer while New Wave focuses on the modeling/simulation layer on top.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
New Wave Biotech social profiles
Digital presenceNew Wave Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
New Wave Biotech leadership team
Management profileNumber of profiles
Profiles2 records
New Wave Biotech funding detail
Funding detailFunding overview
Funding rounds6 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
New Wave Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about New Wave Biotech
What does New Wave Biotech do?
New Wave Biotech develops and sells Bioprocess Foresight, an AI-powered bioprocess simulation platform that virtually tests thousands of downstream processing scenarios to predict yield, unit economics and sustainability impact. The platform combines hybrid AI (mechanistic modeling plus machine learning) with integrated techno-economic analysis and biotech-specific life cycle assessment, enabling biomanufacturers to cut R&D experiments by up to 92% and reach optimal processes faster.
Is New Wave Biotech a public or private company?
New Wave Biotech is a private company. It is classified as venture growth investor backed and is currently operating.
When was New Wave Biotech founded?
New Wave Biotech was founded in 2022. It employs 1 to 10 people.
Where is New Wave Biotech based?
New Wave Biotech is headquartered in London, United Kingdom, in the Europe region.
How does New Wave Biotech make money?
Three revenue lines are on record. Software Platform Subscription is the primary driver. The others are custom Optimization Projects and enterprise Licensing.
Who are New Wave Biotech's main competitors?
Direct peers on record are Culture Biosciences, Synthace and Benchling. Emerging players are Cradle and Insitro. Broad incumbents are Aspen Technology, Ginkgo Bioworks, Sartorius and Cytiva. TetraScience is listed as an others.
Does New Wave Biotech have an API?
No public API is recorded for New Wave Biotech.
What industry is New Wave Biotech in?
New Wave Biotech's product category is Bioprocess Simulation Software. Its primary akta.pro industry code is HLAAAJAF, Bioprocess Development & Scale-Up/Scale-Down Platforms (DoE, high-throughput, modeling), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.